Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Na Wang, Tao Yang, Jie Li & Xianfeng Zhang. (2019) Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes, Metabolic Syndrome and Obesity 12, pages 1513-1526.
Read now
Read now
Sten Madsbad. (2019) Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. Expert Review of Cardiovascular Therapy 17:5, pages 377-387.
Read now
Read now
Articles from other publishers (20)
Ridhi Gudoor, Austen Suits & Jay H. Shubrook. (2023) Perfecting the Puzzle of Pathophysiology: Exploring Combination Therapy in the Treatment of Type 2 Diabetes. Diabetology 4:3, pages 379-392.
Crossref
Crossref
Wanjun Guo, Zheng Xu, Haixia Zou, Feng Li, Yao Li, Jing Feng, Zhiyi Zhu, Qing Zheng, Rui Zhu, Bin Wang, Yan Li, Sujuan Hao, Hong Qin, Catherine L. Jones, Eric Adegbite, Libnir Telusca, Martijn Fenaux, Weidong Zhong, Mohammed K. Junaidi, Susan Xu & Hai Pan. (2023) Discovery of ecnoglutide – A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Molecular Metabolism 75, pages 101762.
Crossref
Crossref
Sten Madsbad & Jens J Holst. (2023) Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. Cardiovascular Research 119:4, pages 886-904.
Crossref
Crossref
Jing-Yue Wang, Quan-Wei Wang, Xin-Yu Yang, Wei Yang, Dong-Rui Li, Jing-Yu Jin, Hui-Cong Zhang & Xian-Feng Zhang. (2023) GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology 14.
Crossref
Crossref
Anniek Frederike Lubberding, Jens Juul Holst & Sten Madsbad. 2023. Cardiovascular Endocrinology and Metabolism. Cardiovascular Endocrinology and Metabolism
365
396
.
Qirou Wang, Jia Wang, Nannan Li, Junyu Liu, Jingna Zhou, Pengwei Zhuang & Haixia Chen. (2022) A Systematic Review of Orthosiphon stamineus Benth. in the Treatment of Diabetes and Its Complications. Molecules 27:2, pages 444.
Crossref
Crossref
Michael Joubert, Victoria Opigez, Barbora Pavlikova, Laure Peyro Saint Paul, Nathalie Jeandidier, Anaïs R. Briant, Jean‐Jacques Parienti & Yves Reznik. (2020)
Efficacy and safety of exenatide as add‐on therapy for patients with type
2
diabetes with an intensive insulin regimen: A randomized double‐blind trial
. Diabetes, Obesity and Metabolism 23:2, pages 374-381.
Crossref
Crossref
Ze-Min Yang, Ying Wang & Si-Yu Chen. (2021) Astragalus polysaccharide alleviates type 2 diabetic rats by reversing the glucose transporters and sweet taste receptors/GLP-1/GLP-1 receptor signaling pathways in the intestine-pancreatic axis. Journal of Functional Foods 76, pages 104310.
Crossref
Crossref
Jana Pyšná, Ladislav Pyšný, David Cihlář, Dominika Petrů & Martin Škopek. (2020) Effect of Physical Activity on Obesity in Second Stage Pupils of Elementary Schools in Northwest Bohemia. Sustainability 12:23, pages 10042.
Crossref
Crossref
Suling Huang, Shanyao Ma, Mengmeng Ning, Wenji Yang, Yangliang Ye, Lina Zhang, Jianhua Shen & Ying Leng. (2019) TGR5 agonist ameliorates insulin resistance in skeletal muscles and improves glucose homeostasis in diabetic mice. Metabolism 99, pages 45-56.
Crossref
Crossref
A.R. Pinho, A. Fortuna, A. Falcão, A.C. Santos, R. Seiça, C. Estevens, F. Veiga & A.J. Ribeiro. (2019) Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices. Journal of Pharmaceutical Analysis 9:3, pages 143-155.
Crossref
Crossref
Sten Madsbad & Jens J. Holst. 2018. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
571
615
.
Sten Madsbad & Jens J. Holst. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
45
.
Wan-Wan Ji, Dong-An Yu, Min Fan, Meng You, You Lu, Er-Bing Li, Ning Xie & Shou-Sheng Yan. (2017) Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice. Acta Diabetologica 54:7, pages 685-693.
Crossref
Crossref
Sten Madsbad & Jens J Holst. (2017) Glycaemic control and weight loss with semaglutide in type 2 diabetes. The Lancet Diabetes & Endocrinology 5:5, pages 315-317.
Crossref
Crossref
M. Joubert & Y. Reznik. (2017) Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure. Diabetes & Metabolism 43, pages 2S34-2S38.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study. Diabetes Therapy 8:2, pages 321-334.
Crossref
Crossref
P. D. Mitchell, B. M. Salter, J. P. Oliveria, A. El-Gammal, D. Tworek, S. G. Smith, R. Sehmi, G. M. Gauvreau, M. Butler & P. M. O'Byrne. (2017) Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clinical & Experimental Allergy 47:3, pages 331-338.
Crossref
Crossref
Thomas Fremming Dejgaard & Sten Madsbad. (2017) Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy. Diabetes, Obesity and Metabolism 19:2, pages 153-155.
Crossref
Crossref
Bosede O. Owolabi, Opeolu O. Ojo, Dinesh K. Srinivasan, J. Michael Conlon, Peter R. Flatt & Yasser H. A. Abdel-Wahab. (2016) Glucoregulatory, endocrine and morphological effects of [P5K]hymenochirin-1B in mice with diet-induced glucose intolerance and insulin resistance. Naunyn-Schmiedeberg's Archives of Pharmacology 389:7, pages 769-781.
Crossref
Crossref